Welcome to our dedicated page for Kindred Bio news (Ticker: KIN), a resource for investors and traders seeking the latest updates and insights on Kindred Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kindred Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kindred Bio's position in the market.
Kindred Biosciences, a biopharmaceutical company focusing on pet medications, will release its Q3 2020 financial results on November 9, 2020, after market close. A conference call will be held at 4:30 p.m. ET, which can be accessed via phone or a live webcast. The company aims to develop safe and effective treatments for pets, leveraging successful human-target therapeutics.
Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV). The study demonstrated 100% efficacy in preventing CPV, with treated dogs showing no mortality compared to 60% in the control group. KIND-030 is being developed both as prophylactic therapy and for treating established CPV infections. The company anticipates completing pivotal safety studies by year-end 2020, with regulatory approval expected in early 2021. This product addresses a significant unmet need given the high mortality rates associated with CPV.
Kindred Biosciences (NASDAQ: KIN), a biopharmaceutical firm focused on pet health, will participate in three upcoming conferences. These include the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17, 2020. CEO Richard Chin will present and hold one-on-one meetings to discuss recent developments, study results, and future milestones. Investors can access webcasts of the presentations through the company's website.
Kindred Biosciences, Inc. (NASDAQ: KIN) reported strong financial results for Q2 2020, with net revenues of $39.6 million and net income of $24.0 million, equating to $0.60 per share. The company highlighted progress on its biologics pipeline, including the initiation of pivotal studies for its canine parvovirus and IL-31 antibody candidates. The sale of Mirataz to Dechra Pharmaceuticals generated significant revenue, although equine product sales were impacted by COVID-19. KindredBio maintains a positive outlook, anticipating operating expenses between $53-$55 million for the year.
Kindred Biosciences, Inc. (NASDAQ: KIN) will announce its second quarter 2020 financial results on August 5, 2020, after market close, followed by a conference call at 4:30 p.m. Eastern time. Investors can access the call toll-free at (888) 771-4371 or internationally at (847) 585-4405 using conference ID 49852246. The call will also be webcast live, with a replay available for 30 days. Kindred aims to develop innovative biologics for pets, paralleling safe and effective human medicines.